Research for Patient Benefit Programme- East Midlands Competition 51 Stage 1 Competition 50 Stage 2 Minutes

Minutes for the Research for Patient Benefit (RfPB) programme East Midlands Regional Advisory Committee meeting to discuss Stage 2 applications to Competition 50 and Stage 1 applications to Competition 51.

Date and Location

Wednesday 20 September 2023 at Burleigh Court, Leicestershire

In attendance

Committee members

Dr Paul Leighton (Chair)
Professor Abhishek Abhishek
Mrs Ajanta Biswas
Professor Jayne Brown
Mr Paul Caulfield
Dr Louise Jackson
Professor Dileep Lobo
Dr Jatinder Minhas
Ms Rachel Neilan
Dr Christopher Partlett
Dr Samuel Seidu
Dr Wendy Wood
Dr Kotera Yasuhiro
Professor Richard Morriss

Secretariat

Dr Nichola Sillett (NIHRCC)
Dr Ianina Conte (NIHRCC)
Ms Rebecca Purvis (NIHRCC)
Ms Harkerat Jandu (NIHRCC)

Competition 50 Stage 2 applications considered

NIHR206141: Investigation and Referral of Suspected Cancer Symptoms in Older Adults living in Care Homes: Developing a Prototype Shared Decision-Making Intervention
Conflicts: None

Final outcome: Reject

NIHR206212: Behaviour change to rEduce LOW back pain: a feasibility study (BELOW)
Conflicts: Dr Paul Leighton

Final outcome: Conditional support

NIHR206158: Developing practice and policy recommendations to support effective therapeutic alliance in inpatient treatment for eating disorders. ALLIANCE study
Conflicts: None

Final outcome: Conditional support

NIHR206170: ?-hydroxy ß-methylbutyrate (HMB) supplementation to improve functional status in people with advanced liver cirrhosis (BOMBER): a multicentre double blind placebo-controlled randomised trial
Conflicts: None

Final outcome: Conditional support

NIHR206222: Co-production of culturally appropriate bite-size videos to facilitate physical activity in people with stroke from South Asian communities.
Conflicts: None

Final outcome: Reject

NIHR206783: A feasibility study of a cluster randomised controlled trial testing a brief behaviour change intervention for patients with periodontal disease
Conflicts: None

Final outcome: Reject

NIHR206145: Decision aid and manual to improve treatment adherence in resistant hypertension: EASY-BP
Conflicts: None

Final outcome: Reject

NIHR206787: Primary care and hospice engagement with communities to think, talk or act on current or future end of life needs: Realist Evaluation of THINK, TALK, ACT (TTA)
Conflicts: Dr Wendy Wood

Final outcome: Reject

NIHR206218: Paediatric Kidney Patient Reported Experience Measure - developing and validating an experience measure for under 18 year olds.
Conflicts: None

Final outcome: Conditional support

Competition 51 Stage 1 applications considered

NIHR206658: Attributes of Donors for Optimal Outcomes in Pancreas Transplantation: a Delphi consensus study (ADOOPT Study)
Conflicts: Dr Paul Leighton

Outcome: Reject

NIHR206661: A tier 2 RfPB feasibility (external pilot) study of Hormone replacement therapy in peri and post-menopausal patients with spontaneous coronary artery dissection with chest pain
Conflicts: Dr Jatinder Minhas and Dr Paul Leighton

Outcome: Invite to Stage 2

NIHR206683: Paediatric Otorrhoea Study (POSt-2): A open-label feasibility randomised trial
Conflicts: None

Outcome: Invite to Stage 2

NIHR206600: Understanding Delays in Organ Donation after Circulatory Death in the UK: An Ethnographic Study
Conflicts: None

Outcome: Invite to Stage 2

NIHR206734: A pragmatic study to determine the effective medication range of two of the most commonly prescribed antihypertensives.
Conflicts: Dr Jatinder Minhas

Outcome: Reject

NIHR206594: Piloting and assessing the feasibility of a co-produced model of care across adolescent secure services in England: Moving Forward intervention (MFi)
Conflicts: None

Outcome: Reject

NIHR206717: Risk of suicide and self-harm in substance misuse: development and validation of two risk prediction rules and their feasibility in clinical practice
Conflicts: None

Outcome: Reject

Outcomes Table

The tables below display the mean scores for each application that was assessed in the regional assessment committee meeting. They exclude applications that were rejected during the scrutiny and triage processes. 

Stage 2

Stage 1